BioSpace News Archive

CSL Vifor and Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).

Moderna, Inc. today announced that the Government of Canada has exercised its option to purchase an additional 4.5 million doses of an Omicron-containing bivalent vaccine booster.

Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the publication of an article entitled “ Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease ” in the American Journal of Preventive Cardiology.

Aurora Spine Corporation today announced it will issue its financial results press release for the second quarter ended June 30, 2022, on Monday, August 29, 2022.

Assure Holdings Corp. today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6.2 million, before deducting underwriting discounts and other estimated expenses payable by the Company.

VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI | OTCQX: VHIBF) is pleased to announce a licensing agreement of subsidiary Intouch with Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis Home and Synopsis iQ, to the Bolton NHS Foundation Trust (the “Trust” or “Bolton”).

PanTher Therapeutics (“PanTher” or the “Company”), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] (the Company) is pleased to advise of outcomes from its collaboration to study the neurological aspects of Long COVID-19 (Long Neuro COVID-19) with US based researchers led by global leader in the field, Dr Igor Koralnik, at the Northwestern Medicine Neuro-COVID clinic in Chicago, USA.

Immunovia will publish its second quarter 2022 results on August 24, 2022 at 8:30 am CET.

Cue Biopharma, Inc. announced today that it has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102, its second clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics.